{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Patient&page=72", "query": { "condition": "Cancer Patient", "page": 72 }, "page_size": 10 }, "pagination": { "page": 72, "page_size": 10, "total_count": 26241, "total_pages": 2625, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Patient&page=73&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Patient&page=71&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T09:46:25.268Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05340621", "title": "NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "RAS Mutation", "NRAS Gene Mutation", "Melanoma" ], "interventions": [ { "name": "OKI-179 + binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OnKure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-05-11", "completion_date": "2025-01-29", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 12, "location_summary": "Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05340621" }, { "nct_id": "NCT02140021", "title": "Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenocarcinoma In Situ", "Cervical Intraepithelial Neoplasia", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Cervical Squamous Intraepithelial Neoplasia", "Early Invasive Cervical Adenocarcinoma", "Early Invasive Cervical Squamous Cell Carcinoma", "High Grade Cervical Squamous Intraepithelial Neoplasia", "High Grade Vaginal Intraepithelial Neoplasia", "Low Grade Vaginal Intraepithelial Neoplasia", "Stage I Cervical Cancer AJCC v8", "Stage I Vaginal Cancer AJCC v8", "Stage I Vulvar Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Vaginal Cancer AJCC v8", "Stage IA Vulvar Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Vaginal Cancer AJCC v8", "Stage IB Vulvar Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Vaginal Cancer AJCC v8", "Stage II Vulvar Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Vaginal Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Vaginal Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage III Vulvar Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Vulvar Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Vulvar Cancer AJCC v8", "Stage IIIC Vulvar Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vaginal Adenocarcinoma", "Vulvar Adenocarcinoma", "Vulvar High Grade Squamous Intraepithelial Lesion", "Vulvar Intraepithelial Neoplasia", "Vulvar Squamous Cell Carcinoma", "Vulvar Squamous Intraepithelial Lesion" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 409, "start_date": "2014-10-27", "completion_date": "2025-07-08", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140021" }, { "nct_id": "NCT01337752", "title": "Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Renal Insufficiency" ], "interventions": [ { "name": "BHQ880", "type": "DRUG" }, { "name": "BHQ880 Placebo", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 9, "start_date": "2012-01", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 2, "location_summary": "Chicago, Illinois • Spokane, Washington", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01337752" }, { "nct_id": "NCT00003058", "title": "Troglitazone in Treating Patients With Liposarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "troglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 85, "start_date": "1997-06", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003058" }, { "nct_id": "NCT00129558", "title": "A Study to Evaluate PT-523 in Patients With Refractory Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "PT-523 for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2005-07", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 6, "location_summary": "Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00129558" }, { "nct_id": "NCT02339558", "title": "Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharynx Carcinoma", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2015-07-21", "completion_date": null, "has_results": true, "last_update_posted_date": "2019-09-13", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02339558" }, { "nct_id": "NCT03404726", "title": "A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "BAY2402234", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-03-29", "completion_date": "2021-01-26", "has_results": false, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 4, "location_summary": "New York, New York • The Bronx, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03404726" }, { "nct_id": "NCT04472026", "title": "AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Thyroid Nodules", "Thyroid Cancer" ], "interventions": [ { "name": "Counseling using the electronic conversation aid", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 66, "start_date": "2020-07-16", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 2, "location_summary": "Gainesville, Florida • Rochester, Minnesota", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04472026" }, { "nct_id": "NCT06747585", "title": "A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Non-small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Cervical Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "ALE.P02", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alentis Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2024-12-16", "completion_date": "2028-08-15", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06747585" }, { "nct_id": "NCT03811015", "title": "Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 636, "start_date": "2019-08-16", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-29T09:46:25.268Z", "location_count": 727, "location_summary": "Fairhope, Alabama • Mobile, Alabama • Anchorage, Alaska + 462 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811015" } ] }